{
  "case_id": "MN23-39327",
  "year": 2023,
  "patient_info": {
    "age_range": "41 to 50",
    "gender": "Female"
  },
  "diagnosis": "CNS Lupus",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Biologics",
  "treatments_requested": [
    {
      "name": "Lupkynis",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": "Used concurrently with cyclophosphamide"
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [],
  "is_denial_upheld": true,
  "issues_considered": [
    "medical_necessity",
    "plan_coverage"
  ],
  "other_issues": null,
  "guidelines_support": false,
  "guidelines_not_support": true,
  "guidelines_details": "FDA approved Lupkynis for active lupus nephritis, not CNS lupus. No established efficacy and safety for combination with cyclophosphamide.",
  "soc_support": false,
  "soc_not_support": true,
  "soc_details": "No current recommendations or clinical trials support the combination for CNS lupus.",
  "study_support": false,
  "study_details": [
    {
      "study_name": "Organ-threatening or life-threatening SLE treatment",
      "study_authors": "Not specified",
      "key_findings": "High-intensity immunosuppressive therapy followed by less intensive therapy is recommended. No data supports Lupkynis with cyclophosphamide for CNS lupus."
    }
  ],
  "key_questions": [
    "medical_necessity",
    "plan_coverage"
  ],
  "expedited": true,
  "rationale": "The requested medication regimen is not medically necessary for CNS lupus as per current medical literature and guidelines. The combination of Lupkynis and cyclophosphamide lacks efficacy and safety data.",
  "reviewer_credentials": "Board certified in rheumatology, actively practicing, expert in treating similar conditions."
}